Theravance Biopharma TBPH Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $167.81M+344% | $37.8M-4.4% | $39.55M-86.7% | $298.17M+231% | ||
| $147.55M+192% | $50.55M-19.6% | $62.88M+115% | $29.31M-64.9% | ||
| $836K0.0% | $836K0.0% | $836K0.0% | $836K-0.1% | ||
| $7.56M+76.9% | $4.28M-63.1% | $11.6M+51.0% | $7.68M-10.3% | ||
| $418.46M+160% | $161.07M+20.6% | $133.54M-62.2% | $353.46M+41.5% | ||
| $5.9M-20.5% | $7.42M-18.2% | $9.07M-23.6% | $11.88M-13.0% | ||
| $24.37M-14.0% | $28.35M-21.9% | $36.29M-9.6% | $40.13M+1.1% | ||
| $24.88M+103% | $12.29M+52.3% | $8.07M+16.9% | $6.9M+114% | ||
| $11.13M— | —— | —— | —— | ||
| $485.57M+37.1% | $354.16M-7.3% | $382M-37.1% | $607.4M+62.1% | ||
| $2.57M+14.5% | $2.24M+47.1% | $1.52M-1.9% | $1.55M-49.8% | ||
| $12.59M+79.4% | $7.02M+8.9% | $6.44M-37.5% | $10.31M-19.4% | ||
| $10.95M+2.2% | $10.71M+173% | $3.92M-41.9% | $6.75M+1,243% | ||
| $38.3M+19.4% | $32.09M+29.5% | $24.77M-13.7% | $28.72M-51.0% | ||
| $31.76M-18.8% | $39.11M-13.5% | $45.24M-0.4% | $45.41M-13.8% | ||
| $313K-83.4% | $1.89M-68.1% | $5.92M+257% | $1.66M-24.0% | ||
| —— | —— | —— | —— | ||
| $1K— | —— | —— | $1K0.0% | ||
| $1.16B+1.3% | $1.14B+1.7% | $1.12B-13.4% | $1.3B-6.6% | ||
| -$859.63M+11.0% | -$965.52M-6.2% | -$909.1M-6.5% | -$853.91M+50.5% | ||
| $61K+771% | $7K+111% | -$65K-333% | -$15K— | ||
| $296.72M+69.0% | $175.55M-17.6% | $213M-51.8% | $441.8M+230% | ||
| $485.57M+37.1% | $354.16M-7.3% | $382M-37.1% | $607.4M+62.1% | ||
| $147.55M+192% | $50.55M-19.6% | $62.88M+115% | $29.31M-64.9% | ||
| $45.54M+147% | $18.44M+5.5% | $17.47M+4.1% | $16.79M+19.3% | ||
| $50M0.0% | $50M— | —— | —— | ||
| $24.88M+103% | $12.29M+52.3% | $8.07M+16.9% | $6.9M+114% | ||
| $24.37M-14.0% | $28.35M-21.9% | $36.29M-9.6% | $40.13M+1.1% | ||
| $11.13M— | —— | —— | —— | ||
| $24.37M-14.0% | $28.35M-21.9% | $36.29M-9.6% | $40.13M+1.1% | ||
| $24.88M+103% | $12.29M+52.3% | $8.07M+16.9% | $6.9M+114% | ||
| $24.37M-14.0% | $28.35M-21.9% | $36.29M-9.6% | $40.13M+1.1% | ||
| $24.88M+103% | $12.29M+52.3% | $8.07M+16.9% | $6.9M+114% | ||
| $12.59M+79.4% | $7.02M+8.9% | $6.44M-37.5% | $10.31M-19.4% | ||
| $3.37M+219% | $1.06M-52.9% | $2.25M-54.5% | $4.93M-71.0% | ||
| $2.05M-31.3% | $2.99M+3.0% | $2.9M-27.9% | $4.02M+38.7% | ||
| $5.29M-9.7% | $5.85M— | —— | —— | ||
| $12.59M+79.4% | $7.02M+8.9% | $6.44M-37.5% | $10.31M-19.4% | ||
| $42.7M-14.3% | $49.82M+1.3% | $49.16M-5.8% | $52.16M-1.9% | ||
| $1K— | —— | —— | $1K0.0% | ||
| $32.8M+8.1% | $30.33M+9.2% | $27.79M+9.2% | $25.44M— | ||
| $1.49M-32.9% | $2.21M+78.4% | $1.24M+8.7% | $1.14M-12.4% | ||
| $85.68M+13.9% | $75.2M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Theravance Biopharma's total assets?
- Theravance Biopharma (TBPH) holds $472.3M in total assets, up 37.5% year over year.
- How much debt does Theravance Biopharma have?
- Theravance Biopharma carries $40.5M in total debt against $290.6M of shareholders' equity, a debt-to-equity ratio of 0.14.
- How much cash does Theravance Biopharma have?
- Theravance Biopharma holds $288.1M in cash and equivalents.
- Can Theravance Biopharma cover its short-term obligations?
- Its current ratio is 13.14 — current assets exceed current liabilities.
- Where does Theravance Biopharma's balance sheet data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
